title: Lack of association between anti-V3 loop antibodies and perinatal transmission of HIV-1 in Kampala, Uganda.
abstract: This study evaluated the association between reactivity of maternal antibody to human immunodeficiency virus type 1 (HIV-1) V3 loop peptides and perinatal transmission in Uganda. Plasma from 40 HIV-1-infected mothers (20 transmitting and 20 nontransmitting mothers) and 31 uninfected mothers in Uganda were tested for reactivity and antibody titer to synthetic peptides representing V3 loop sequences from HIV-1 strains MN, SF2, LAI, ZR6, and CM235 and consensus peptides CA, CB, and CD. No significant differences were found between 20 transmitting mothers and 20 nontransmitting mothers in terms of percent reactivity or titer of antibody to any of the V3 loop peptides tested. Use of a multivariable logistic model to adjust for beta-2 microglobulin level as a confounding variable of stage of infection did not help demonstrate an association except possibly for the ZR6 peptide. These data suggest that neither reactivity nor maternal antibody titer to V3 loop peptides are protective against perinatal transmission of HIV-1 in Uganda.
authors.affiliation: Department of Biochemistry, Makerere University, Kampala, Uganda.
authors.forename: H
authors.initials: H
authors.lastname: Epstein
authors.forename: L
authors.initials: L
authors.lastname: Guay
authors.forename: D
authors.initials: D
authors.lastname: Hom
authors.forename: F
authors.initials: F
authors.lastname: Mmiro
authors.forename: C
authors.initials: C
authors.lastname: Ndugwa
authors.forename: L
authors.initials: L
authors.lastname: Marum
authors.forename: K
authors.initials: K
authors.lastname: Olness
authors.forename: E
authors.initials: E
authors.lastname: Piwowar
authors.forename: P
authors.initials: P
authors.lastname: Kataaha
authors.forename: J
authors.initials: J
authors.lastname: Baenziger
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000635:transmission; D000595:Amino Acid Sequence; D016022:Case-Control Studies; D005260:Female; D015483:HIV Antibodies / Q000096:biosynthesis*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D018023:HIV Seronegativity / Q000276:immunology; D006679:HIV Seropositivity / Q000276:immunology; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000276:immunology*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology* / Q000821:virology; D014454:Uganda / Q000453:epidemiology
chemical_list: D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments